Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Company’s proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Company's legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. Exemplar segment is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar (Exemplar), its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
종목 코드 PGEN
회사 이름Precigen Inc
상장일Aug 08, 2013
CEODr. Helen Sabzevari, Ph.D.
직원 수143
유형Ordinary Share
회계 연도 종료Aug 08
주소20374 Seneca Meadows Parkway
도시GERMANTOWN
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호20876
전화13015569900
웹사이트https://precigen.com/
종목 코드 PGEN
상장일Aug 08, 2013
CEODr. Helen Sabzevari, Ph.D.
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음